Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy

Clinical and Translational Oncology

Volumn 14, Issue 2, 2012, Pages 150-156

  Lowes, Lori E ^a,b   Lock, Michael ^a,b   Rodrigues, George ^a,b   D'Souza, David ^a,b   Bauman, Glenn ^a,b   Ahmad, Belal ^a,b   Venkatesan, Varagur ^a,b   Allan, Alison L ^a,b   Sexton, Tracy ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Circulating; Neoplastic cells; Prostate specific antigen; Prostatic neoplasms; Radiotherapy; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; AUTOANALYZER; BLOOD EXAMINATION; BLOOD LEVEL; BLOOD SAMPLING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CELL COUNT; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; INTENSITY MODULATED RADIATION THERAPY; PILOT STUDY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN BLOOD LEVEL; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT RESPONSE;

BRACHYTHERAPY; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 84860711493     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0775-5     Document Type: Article

References (21)

1. Canadian Cancer Statistics, 2010. Canadian Cancer Society, Toronto. Available at: www.cancer.ca
2. Chalasani V, Iansavichene AE, Lock M, Izawa JI (2009) Salvage radiotherapy following radical prostatectomy. Int J Urol 16:31-36
3. Ohori M, Goad JR, Wheeler TM et al (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843-1849 (Pubitemid 24322642)
4. Pound CR, Partin AW, Eisenberger MA, Pearson JD (1997) Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin N Am 24:395-406 (Pubitemid 27169264)
5. Lee AK, D'Amico AV (2005) Utility of prostatespecific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23:8192-8197 (Pubitemid 46211554)
6. Maier J, Forman J, Tekyi-Mensah S et al (2004) Salvage radiation for a rising PSA following radical prostatectomy. Urol Oncol 22:50-56 (Pubitemid 38542714)
7. Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specifi c biological properties of disseminating tumour cells. Nat Rev Cancer 8:329-340 (Pubitemid 351596394)
8. de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefi t from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309
9. Mostert B, Sleijfer S, Foekens JA, Gratama JW (2009) Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 35:463-474
10. Cohen SJ, Punt CJA, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213-3221
11. Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791 (Pubitemid 39095313)
12. Tombal B, Van Cangh PJ, Loric S, Gala JL (2003) Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Prostate 56:163-170 (Pubitemid 36918166)
13. Allard WJ, Matera J, Miller MC et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904 (Pubitemid 39383039)
14. Davis JW, Nakanishi H, Kumar VS et al (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specifi c antigen: initial results in early prostate cancer. J Urol 179:2187-2191
15. Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041 (Pubitemid 46972788)
16. Allan AL, Keeney M (2010) Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010:426218
17. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454
18. Lilja H, Ulmert D, Vickers AJ (2008) Prostatespecifi c antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8:268-278 (Pubitemid 351430866)
19. Zegarra-moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgenrefractory prostate cancer cells. Cell Proliferat 62:1008-1013 (Pubitemid 34160279)
20. Yoshimoto M, Cunha IW, Coudry RA et al (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97:678-685 (Pubitemid 47339893)
21. Tomlins SA, Mehra R, Rhodes DR et al (2006) TMPRSS2:ETV4 gene fusions defi ne a third molecular subtype of prostate cancer. Cancer Res 66:3396-3400